JOHNS HOPKINS BAYVIEW MED. CTR.
1. Target Overview & Investment Thesis
JOHNS HOPKINS BAYVIEW MED. CTR. is a 424-bed suburban community hospital in BALTIMORE CITY, MD with $654.4M in net patient revenue and a -17.1% operating margin. The hospital serves a payer mix of 35.0% Medicare, 15.2% Medicaid, and 49.8% commercial.
Thesis: Undervalued. Our ML models identify $48.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -17.1% to -9.8% (+736bps).
| Net Revenue HCRIS | $654.4M |
| Current EBITDA COMPUTED | $-112.0M |
| Operating Margin COMPUTED | -17.1% |
| Occupancy HCRIS | 73.8% |
| Revenue / Bed COMPUTED | $1.5M |
| Net-to-Gross HCRIS | 81.8% |
| Distress Probability ML | 52.1% |
2. Market Context & Competitive Position
MD has 59 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -17.1% places it below the state median. Among 19 size-comparable peers (212-848 beds), the median margin is -8.5%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (212-848), prioritizing same-state peers. 19 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| JOHNS HOPKINS BAYVIEW MED. CTR (Target) | MD | 424 | $654.4M | -17.1% |
| UNIVERSITY OF MARYLAND MED SYS | MD | 779 | $1.85B | -50.0% |
| SINAI HOSPITAL OF BALTIMORE I | MD | 459 | $820.9M | -20.6% |
| ANNE ARUNDEL MEDICAL CENTER IN | MD | 379 | $616.6M | -3.3% |
| MEDSTAR FRANKLIN SQUARE MEDICA | MD | 354 | $537.6M | -5.7% |
| HOLY CROSS HOSPITAL | MD | 399 | $516.0M | -16.7% |
| TIDALHEALTH PENINSULA REGIONAL | MD | 230 | $493.4M | 0.8% |
| AHC SHADY GROVE MEDICAL CENTER | MD | 381 | $446.5M | -3.8% |
| BALTIMORE WASHINGTON MEDICAL C | MD | 314 | $440.2M | -7.9% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $48.2M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $13.7M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $13.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $13.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $8.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $419K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-112.0M |
| + RCM Uplift | +$48.2M |
| Pro Forma EBITDA | $-63.8M |
| Current Margin | -17.1% |
| Pro Forma Margin | -9.8% |
| WC Released (1x) | $25.1M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-172.3M | $-257.0M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-172.3M | $-338.7M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-155.1M | $-235.7M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-155.1M | $-302.9M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-189.5M | $-441.9M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-189.5M | $-547.6M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| High | Elevated distress probability | Model estimates 52.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 19 hospitals with 212-848 beds
- Same-state prioritization (n=20)
- Comp margins: P25=-17.7% / P50=-8.5% / P75=-3.7%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.